Pacific Edge shares fall 63% after Novitas decision

Pacific Edge shares fall 63% after Novitas decision
(Image: Pacific Edge)
Rebecca Howard
Cancer diagnostics company Pacific Edge has come out swinging against a decision by Novitas, the Medicare administrative contractor with jurisdiction for its US laboratory, that would end reimbursement for Cxbladder Triage, Detect and Monitor. The shares fell 63% to $0.050 in early trading Monday after a trading halt was lifted.According to Pacific Edge, Novitas continues to misunderstand the current standard of care in evaluating hematuria patients, fails to consider new peer-reviewed evidence and repeats its flawed analysis of the existi...

More Markets

NZ sharemarket down 0.2% as Trump retakes office
Markets Market Close

NZ sharemarket down 0.2% as Trump retakes office

The S&P/NZX 50 Index closed at 13.052.9, down 35.41 points or 0.27%.

Graham Skellern 21 Jan 2025
Rua Bioscience psilocybin study targets meth addiction
Markets

Rua Bioscience psilocybin study targets meth addiction

The ‘preparation step’ will be followed by an ‘experiential session’ with the mushroom.

Gregor Thompson 21 Jan 2025
Jarden sees Mercury, Genesis upside
Markets

Jarden sees Mercury, Genesis upside

Energy margin data points to earnings upgrades for both gen-tailers.

Pattrick Smellie 21 Jan 2025
Cooks Coffee continues strong sales growth
Retail

Cooks Coffee continues strong sales growth

The sales growth comes at a time of rapid expansion for the firm.

Staff reporters 21 Jan 2025